Hospital APPE project
Hi! I am in need of some great ideas for a project I am doing for my hospital APPE. What do you think are some pharmacy areas of improvement for central hospital pharmacists? I am thinking of choosing a topic (Ex. efficacy of DOACs and ensuring adherence) and seeing how the data differs from the hospital I am currently at (ex. why pts on DOACs are in the hospital) and then how pharmacy can increase adherence (ex. switching from apixaban to dabigatran with a 340b program, giving medication...
Read more (Source: Student Doctor Network)
Source: Student Doctor Network - December 9, 2023 Category: Universities & Medical Training Authors: hawaii1234 Tags: Pharmacy Source Type: forums
Net clinical benefit of dabigatran vs. warfarin: Nothing. Zero.
(Source: BMJ Comments)
Source: BMJ Comments - November 15, 2017 Category: General Medicine Source Type: forums
Idarucizumab – Antidote for hemorrhage following therapeutic dabigatran dosing?
(Source: BMJ Comments)
Source: BMJ Comments - June 23, 2017 Category: General Medicine Source Type: forums
Re: Bleeding risk higher with rivaroxaban than dabigatran for stroke prevention, head-to-head trial shows
(Source: BMJ Comments)
Source: BMJ Comments - October 5, 2016 Category: Journals (General) Source Type: forums
NOAC`s in tripletherapy
New knowledge to low dosed NOAC`s in triple therapy according to european guidelines and the following article: "Comparartive efficacy and safety of novel oral anticoagulants in patients with atrial fibrillation: A network meta-analysis with the adjustment for the possible bias from open label studies", published from Dr. Morimoto T, et al. in the Journal of Cardiology in July, 7 of 2015 . There are statistical significant fewer major bleedings under Edoxaban 30 mg than under Dabigatran 110 mg while both medicines are statistically equal in efficacy. Under Rivaroxaban 15 mg there are statistically significant fewer strokes...
Source: Doc2Doc BMJ Cardiology - November 1, 2015 Category: Cardiology Authors: Mr.Study Source Type: forums
What is the future of "Triple Therapy" after coronary stenting?
Identifying the optimal regimen for antiplatelet therapy in patients requiring long-term anticoagulation following coronary stenting is an area that has traditionally been understudied. Although all major guidelines recommend (limited) triple therapy in this situation, these recommendations are either result of expert consensus or are largely based on observational data.
The WOEST trial was an open-labelled randomised trial and compared dual therapy (a combination of clopidogrel and vitamin K antagonist) with triple therapy (Aspirin, clopidogrel and vitamin K antagonist) in patients undergoing coronary stent...
Source: Doc2Doc BMJ Cardiology - November 17, 2014 Category: Cardiology Authors: Heart Matters Source Type: forums
what do you think of dabigatran?
I have just been looking at the article on dabigatran in this weeks journal
http://www.bmj.com/content/349/bmj.g4670
personally I have not prescribed much dabigatran . Has anyone had enoguh experience to understand the bleeding risk?
sadian (Source: Doc2Doc BMJ Cardiology)
Source: Doc2Doc BMJ Cardiology - July 26, 2014 Category: Cardiology Authors: sadian Source Type: forums
is warfarin heading for a comeback?
I was looking at the re-align study of anticoagulation in mechanical valves that compared warfarin with dabigatran. In this group dabigatran was associated with more bleeding and thrombosis complications. Is warfarin heading for a comeback?
http://www.nejm.org/doi/full/10.1056/NEJMoa1300615
sadian (Source: Doc2Doc BMJ Cardiology)
Source: Doc2Doc BMJ Cardiology - November 14, 2013 Category: Cardiology Authors: sadian Source Type: forums
FDA Investigation Finds No Excess Bleeding Risk for Dabigatran
In its latest assessment of a highly controversial issue, the FDA has found no indication that bleeding rates for dabigatran (Pradaxa, Boehringer-Ingelheim) are any higher than the bleeding rates for warfarin. The FDA investigation was in response to the large number of post-marketing reports of bleeding in people taking dabigatran. Click here to for the full FDA statement. Here is the first paragraph of the statement:
The U.S. Food and Drug Administration (FDA) has evaluated new information about the risk of serious bleeding associated with use of the anticoagulants (blood thinners) dabigatran (Pradaxa) and warfarin (Co...
Source: CardiologyNetwork.com - October 13, 2013 Category: Cardiology Authors: Indian Diabetics Foundation Team Source Type: forums
